BELLESE TECHNOLOGIES, LLC: $25.8M Department of Health and Human Services Contract
Summary
This $25.8M contract to private firm Bellese Technologies for CMS hospital quality reporting is a sector signal for healthcare IT spending, but no publicly traded company is directly tied. The award aligns with healthcare transparency bills like HR8324, but lacks a public beneficiary.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.Bellese Technologies is private; no public ticker exposure.
- 2.Contract is a routine bridge renewal for hospital quality reporting.
- 3.Healthcare IT sector remains stable but no catalyst from this award.
Market Implications
This contract does not directly affect any publicly traded company, so market implications are minimal. The healthcare IT sector may see indirect benefits from sustained government spending on quality reporting, but without a public recipient, no stock movement is expected. Investors should monitor future awards to public firms like Cerner (now Oracle Health) or Epic Systems (private) for clearer signals.
Full Analysis
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
ANGEL DESIGN BUILD CONSTRUCTION LLC: $12.4M Department of Veterans Affairs Contract
GENERAL DYNAMICS INFORMATION TECHNOLOGY, INC.: $14.4M Department of Health and Human Services Contract
GOLDMAN EDWARDS - TANTUS TECHNOLOGIES, LLC: $17.8M Department of Health and Human Services Contract
ALBERT B. SABIN VACCINE INSTITUTE, INC. (THE): $224M Department of Health and Human Services Contract
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Integrating Financial Technology Innovation into Regulatory Frameworks
This executive order directs federal financial regulators to review and streamline regulations that hinder fintech innovation, particularly for small and emerging firms, and requests the Federal Reserve to evaluate expanding access to its payment accounts and services for non-bank and digital asset firms. It aims to reduce barriers to entry and encourage partnerships between fintech firms and traditional financial institutions, with specific deadlines for reviews and reports.
Promoting Efficiency, Accountability, and Performance in Federal Contracting
This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.
Accelerating Medical Treatments for Serious Mental Illness
This executive order directs the FDA to prioritize review and facilitate 'Right to Try' access for psychedelic drugs, including ibogaine compounds, that have received Breakthrough Therapy designation for serious mental illnesses. It also allocates $50 million from HHS to support state programs advancing these treatments and mandates collaboration between HHS, FDA, VA, and the private sector to increase clinical trial participation and data sharing for these drugs. The Attorney General is further directed to expedite rescheduling reviews for approved Schedule I psychedelic substances.
Contract Details
Recipient
BELLESE TECHNOLOGIES, LLC
Award Amount
$25,772,226
Awarding Agency
Department of Health and Human Services
Sub-Agency
Centers for Medicare and Medicaid Services
Contract Type
DELIVERY ORDER
Related Bills